Literature DB >> 11024124

Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils.

A M Joseph1, G J Babcock, D A Thorley-Lawson.   

Abstract

In this paper we demonstrate, for the first time, that Epstein-Barr virus (EBV)-infected cells expressing the lymphoblastoid growth program are present in healthy carriers of the virus. Previously we observed that latently infected naive B cells are present in tonsils only when viral replication is detected, suggesting that these may represent newly infected B cells. We have tested this idea by performing a reverse transcription-PCR analysis for the expression of latent genes (EBNA2 and the EBNA3s) that are characteristically expressed only by newly infected cells expressing the growth latency program. EBNA2 expression is regularly detected in purified naive (IgD(+)) tonsillar B cells (13 of 16 tonsils tested) but was never found in the IgD(-) population (0 of 16). More detailed analysis revealed that the mRNAs for the latent genes EBNA1 (3 of 3 tonsils tested), EBNA3a (3 of 5), EBNA3b (3 of 5), EBNA3c (3 of 5), LMP1 (6 of 6), and LMP2 (5 of 6) were also present in the IgD(+) population, but the EBNA1Q-K transcript, characteristic of nonlymphoblastoid forms of latency, was never detected (0 of 6). Finally, we demonstrate that the latently infected naive (IgD(+)) cells express CD80 (B7.1), a marker characteristically expressed on activated naive lymphoblasts but absent from resting naive B cells. The infected naive (IgD(+)) population in the tonsil therefore has the viral and cellular phenotype of a B-cell directly infected with EBV-an activated lymphoblast expressing the growth program.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11024124      PMCID: PMC102034          DOI: 10.1128/jvi.74.21.9964-9971.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals.

Authors:  J A Thomas; N A Hotchin; M J Allday; P Amlot; M Rose; M Yacoub; D H Crawford
Journal:  Transplantation       Date:  1990-05       Impact factor: 4.939

2.  Epstein-Barr virus latent gene expression during the initiation of B cell immortalization.

Authors:  M J Allday; D H Crawford; B E Griffin
Journal:  J Gen Virol       Date:  1989-07       Impact factor: 3.891

3.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.

Authors:  L Young; C Alfieri; K Hennessy; H Evans; C O'Hara; K C Anderson; J Ritz; R S Shapiro; A Rickinson; E Kieff
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

4.  B7, a B-cell-restricted antigen that identifies preactivated B cells.

Authors:  A S Freedman; G Freeman; J C Horowitz; J Daley; L M Nadler
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

Review 5.  A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells.

Authors:  D A Thorley-Lawson; G J Babcock
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

6.  Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.

Authors:  R Fåhraeus; H L Fu; I Ernberg; J Finke; M Rowe; G Klein; K Falk; E Nilsson; M Yadav; P Busson
Journal:  Int J Cancer       Date:  1988-09-15       Impact factor: 7.396

7.  EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency.

Authors:  J Kurth; T Spieker; J Wustrow; G J Strickler; L M Hansmann; K Rajewsky; R Küppers
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

8.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.

Authors:  F Wang; S F Tsang; M G Kurilla; J I Cohen; E Kieff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Epstein-Barr virus gene expression in nasopharyngeal carcinoma.

Authors:  L S Young; C W Dawson; D Clark; H Rupani; P Busson; T Tursz; A Johnson; A B Rickinson
Journal:  J Gen Virol       Date:  1988-05       Impact factor: 3.891

10.  Early events in Epstein-Barr virus infection provide a model for B cell activation.

Authors:  D A Thorley-Lawson; K P Mann
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  47 in total

1.  Epstein-Barr virus and the somatic hypermutation of immunoglobulin genes in Burkitt's lymphoma cells.

Authors:  R S Harris; D S Croom-Carter; A B Rickinson; M S Neuberger
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression.

Authors:  Barbro Ehlin-Henriksson; John Gordon; George Klein
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

3.  Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus.

Authors:  Takashi Nakayama; Kunio Hieshima; Daisuke Nagakubo; Emiko Sato; Masahiro Nakayama; Keisei Kawa; Osamu Yoshie
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

4.  Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells.

Authors:  Donna Hochberg; Tatyana Souza; Michelle Catalina; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 5.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

6.  Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.

Authors:  Manuel Albanese; Takanobu Tagawa; Mickaël Bouvet; Liridona Maliqi; Dominik Lutter; Jonathan Hoser; Maximilian Hastreiter; Mitch Hayes; Bill Sugden; Larissa Martin; Andreas Moosmann; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

7.  Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β1-induced B-cell apoptosis.

Authors:  Eva M Campion; Roya Hakimjavadi; Sinéad T Loughran; Susan Phelan; Sinéad M Smith; Brendan N D'Souza; Rosemary J Tierney; Andrew I Bell; Paul A Cahill; Dermot Walls
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

8.  Epstein-Barr virus can establish infection in the absence of a classical memory B-cell population.

Authors:  Margaret Conacher; Robin Callard; Karen McAulay; Helen Chapel; David Webster; Dinakantha Kumararatne; Anita Chandra; Gavin Spickett; Paul A Hopwood; Dorothy H Crawford
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide.

Authors:  Christopher J Farrell; Jae Myun Lee; Eui-Cheol Shin; Marek Cebrat; Philip A Cole; S Diane Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-19       Impact factor: 11.205

10.  Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas.

Authors:  Olga Balague Ponz; German Ott; Robert P Hasserjian; Kojo S J Elenitoba-Johnson; Laurence de Leval; Daphne de Jong
Journal:  J Hematop       Date:  2009-06-16       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.